<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7594847</article-id><article-id pub-id-type="pmid">33103482</article-id><article-id pub-id-type="doi">10.1080/14756366.2020.1838501</article-id><article-id pub-id-type="publisher-id">1838501</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Activation of carbonic anhydrases from human brain by amino alcohol oxime ethers: towards human carbonic anhydrase VII selective activators</article-title><alt-title alt-title-type="left-running-head">A. Nocentini et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3342-702X</contrib-id><name><surname>Nocentini</surname><given-names>Alessio</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8842-542X</contrib-id><name><surname>Cuffaro</surname><given-names>Doretta</given-names></name><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="author-notes" rid="FN0001"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2762-1929</contrib-id><name><surname>Ciccone</surname><given-names>Lidia</given-names></name><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="author-notes" rid="FN0001"/></contrib><contrib contrib-type="author"><name><surname>Orlandini</surname><given-names>Elisabetta</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Nencetti</surname><given-names>Susanna</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2669-5376</contrib-id><name><surname>Nuti</surname><given-names>Elisa</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6795-8091</contrib-id><name><surname>Rossello</surname><given-names>Armando</given-names></name><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4262-0323</contrib-id><name><surname>Supuran</surname><given-names>Claudiu T.</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0002"/></contrib><aff id="AF0001"><label>a</label><institution>Section of Pharmaceutical and Nutraceutical Sciences, Department of Neuroscience, Psychology, Drug Research and Child&#x02019;s Health (Neurofarba), University of Florence</institution>, <city>Sesto Fiorentino</city>, <country>Italy</country></aff><aff id="AF0002"><label>b</label><institution>Department of Pharmacy, University of Pisa</institution>, <city>Pisa</city>, <country>Italy</country></aff></contrib-group><author-notes><fn id="FN0001"><label>*</label><p>These authors contributed equally to this work.</p></fn><corresp id="AN0001">CONTACT Armando Rossello <email>armando.rossello@unipi.it</email><institution>Department of Pharmacy, University of Pisa</institution>, <addr-line>via Bonanno 6</addr-line>, <city>Pisa</city>, <postal-code>56126</postal-code>, <country>Italy</country>; </corresp><corresp id="AN0002">Claudiu T. Supuran <email>claudiu.supuran@unifi.it</email><institution>Section of Pharmaceutical and Nutraceutical Sciences, Department of Neuroscience, Psychology, Drug Research and Child&#x02019;s Health (Neurofarba), University of Florence</institution>, <addr-line>via Ugo Schiff 6</addr-line>, <city>Sesto Fiorentino</city>, <postal-code>50019</postal-code>, <country>Italy</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>10</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>36</volume><issue>1</issue><fpage seq="4">48</fpage><lpage>57</lpage><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_36_1838501.pdf"/><abstract><title>Abstract</title><p>The synthesis and carbonic anhydrase (CA; EC 4.2.1.1) activating effects of a series of oxime ether-based amino alcohols towards four human (h) CA isoforms expressed in human brain, hCA I, II, IV and VII, are described. Most investigated amino alcohol derivatives induced a consistent activation of the tested CAs, with K<sub>A</sub>s spanning from a low micromolar to a medium nanomolar range. Specifically, hCA II and VII, putative main CA targets when central nervous system (CNS) diseases are concerned, were most efficiently activated by these oxime ether derivatives. Furthermore, a multitude of selective hCA VII activators were identified. As hCA VII is one of the key isoforms involved in brain metabolism and other brain functions, the identified potent and selective hCA VII activators may be considered of interest for investigations of various therapeutic applications or as lead compounds in search of even more potent and selective CA activators.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Metalloenzyme</kwd><kwd>activation</kwd><kwd>selectivity</kwd><kwd>CNS-disease</kwd><kwd>cognition</kwd></kwd-group><counts><fig-count count="4"/><table-count count="1"/><page-count count="10"/><word-count count="7476"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Activators of the metalloenzymes carbonic anhydrases (CAs; EC 4.2.1.1, CAAs) have been lately going through a second youth in drug discovery processes<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. Early evidence of the CA activation efficacy of amines, such as histamine, dating back to the 1940s was thereafter long debated up, and even considered as an experimental artefact<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref>. In the early 1990s, the combination of highly purified enzymes and precise techniques, such as the stopped flow assay, put an end to the long controversy, testifying the undeniable existence of CAAs<xref rid="CIT0004" ref-type="bibr"><sup>4&#x02013;7</sup></xref>. CAAs intervene in the second and rate determining step of the catalytic mechanism of carbon dioxide reversible hydration (<xref ref-type="disp-formula" rid="M0001">Equations 1</xref> and <xref ref-type="disp-formula" rid="M0002">2</xref>), that is the regeneration of the catalytically active, zinc hydroxide species, by a proton transfer reaction from the Zn<sup>2+</sup> &#x02013; bound water molecule to the external medium (<xref ref-type="disp-formula" rid="M0002">Equation 2</xref>)<xref rid="CIT0006" ref-type="bibr"><sup>6&#x02013;8</sup></xref>. This process is assisted by active site residues acting as proton shuttle, such as His residues placed in the middle or at the entrance of the active site cavity of the &#x003b1;-class human CAs<xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref>.
<disp-formula id="M0001"><label>(1)</label><alternatives><graphic xlink:href="IENZ_A_1838501_M0001.jpg" position="float" orientation="portrait"/><mml:math id="d2e269"><mml:mrow><mml:msup><mml:mrow><mml:mtext>EZn</mml:mtext></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mtext>OH</mml:mtext></mml:mrow><mml:mo>&#x02212;</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mtext>CO</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mi>&#x021c4;</mml:mi><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:msup><mml:mrow><mml:mtext>EZn</mml:mtext></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo>&#x02212;</mml:mo><mml:msubsup><mml:mrow><mml:mtext>HCO</mml:mtext></mml:mrow><mml:mn>3</mml:mn><mml:mo>&#x02212;</mml:mo></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mtext>&#x000a0;H</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mi>&#x021c4;</mml:mi><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:msup><mml:mrow><mml:mtext>EZn</mml:mtext></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mtext>OH</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mtext>HCO</mml:mtext></mml:mrow><mml:mn>3</mml:mn><mml:mo>&#x02212;</mml:mo></mml:msubsup></mml:mrow></mml:math></alternatives></disp-formula>
<disp-formula id="M0002"><label>(2)</label><alternatives><graphic xlink:href="IENZ_A_1838501_M0002.jpg" position="float" orientation="portrait"/><mml:math id="d2e344"><mml:mrow><mml:msup><mml:mrow><mml:mtext>EZn</mml:mtext></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mtext>OH</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mi>&#x021c4;</mml:mi><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:msup><mml:mrow><mml:mtext>EZn</mml:mtext></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo></mml:mrow></mml:msup><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mtext>OH</mml:mtext></mml:mrow><mml:mo>&#x02212;</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mtext>&#x000a0;H</mml:mtext></mml:mrow><mml:mo>+</mml:mo></mml:msup></mml:mrow></mml:math></alternatives></disp-formula>
<disp-formula id="M0003"><label>(3)</label><alternatives><graphic xlink:href="IENZ_A_1838501_M0003.jpg" position="float" orientation="portrait"/><mml:math id="d2e383"><mml:msup><mml:mrow><mml:mtext>EZn</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mtext>OH</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mi>&#x021c4;</mml:mi><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mo stretchy="true">[</mml:mo><mml:msup><mml:mrow><mml:mtext>EZn</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mtext>OH</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">A</mml:mi><mml:mo stretchy="true">]</mml:mo><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mi>&#x021c4;</mml:mi><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mo stretchy="true">[</mml:mo><mml:msup><mml:mrow><mml:mtext>EZn</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mtext>OH</mml:mtext></mml:mrow><mml:mo>&#x02212;</mml:mo></mml:msup><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mtext>AH</mml:mtext></mml:mrow><mml:mo>+</mml:mo></mml:msup><mml:mo stretchy="true">]</mml:mo><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mi>&#x021c4;</mml:mi><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:msup><mml:mrow><mml:mtext>EZn</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mtext>OH</mml:mtext></mml:mrow><mml:mo>&#x02212;</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mtext>AH</mml:mtext></mml:mrow><mml:mo>+</mml:mo></mml:msup></mml:math></alternatives></disp-formula>
</p><p>The activators non-competitively activate the CAs through the formation of a ternary complex consisting of the enzyme, the substrate, and the activator. CAAs bind apart from the metal-coordination system, namely at the middle edge of CAs active site cavity, where they assist the proton shuttling<xref rid="CIT0009" ref-type="bibr"><sup>9&#x02013;11</sup></xref>. As a proof of this phenomenon, it was demonstrated that efficient activators possess p<italic>K</italic><sub>a</sub> values in the range of 6&#x02013;8, values similar to the p<italic>K</italic><sub>a</sub> of the His imidazole moiety<xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref>.</p><p>It is seemingly odd that CAs, among the most efficient enzymes in Nature, may be activated for biomedical purposes<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>. However, genetic deficiencies of several CA isoforms (e.g. human CA I, II, IV, VA, XII and XIV) have been reported in the last decades, associated to diseases such as osteopetrosis, cerebral calcifications, retinal problems, hyperammonaemia, hyperchlorhydrosis<xref rid="CIT0012" ref-type="bibr"><sup>12&#x02013;15</sup></xref>, and the loss of function of these enzymes would in principle be treatable with CA selective activators<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>. In addition, there is evidence that CAs activation improves memory deficits, cognitive performance and learning<xref rid="CIT0016" ref-type="bibr"><sup>16&#x02013;18</sup></xref>, being nine of the fifteen known human CA isoforms present in brain<xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>. Contrariwise, other evidence supported that CA inhibitors (CAIs) impair memory in human, according to studies on the CAIs topiramate and acetazolamide during acute high-altitude exposure<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>. Thus, CAs represent a crucial family of new targets for improving cognition, but also in therapeutic areas, such as phobias, obsessive-compulsive disorder, generalised anxiety, and post-traumatic stress disorders, for which few effective therapies are available. In fact, in a recent paper, one of our groups showed that the CAA D-phenylalanine and the CAI acetazolamide are respectively able to reinforce and impair extinction memory, that is, a new memory trace that inhibits the expression of the memory of a traumatic event<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>. In this golden period for CAAs, the discovery of new brain isoform selective CAAs (as well as CAIs) is invaluable to elucidate the role of CA isoforms in brain processes. In addition, CAAs are considered relevant in artificial tissues and in CO<sub>2</sub> capture and sequestration processes<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref>.</p><p>Here, we extend the knowledge of CAA chemotypes by describing the synthesis and CA activating effects of a series of oxime ether based amino alcohols towards four hCA isoforms expressed in human brain.</p></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Material and methods</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Chemistry</title><p><sup>1</sup>H and <sup>13&#x02009;</sup>C NMR spectra were recorded on a Bruker Avance III HD 400&#x02009;MHz spectrometer. Chemical shifts (&#x003b4;) are reported in parts per million and coupling constants (<italic>J</italic>) are reported in hertz (Hz). <sup>13&#x02009;</sup>C NMR spectra were fully decoupled. The following abbreviations were used to explain multiplicities: singlet (s), doublet (d), triplet (t), double doublet (dd), broad (br), and multiplet (m). Chromatographic separations were performed on silica gel columns by flash column chromatography (Kieselgel 40, 0.040&#x02212;0.063&#x02009;mm, Merck). Reactions were followed by thin-layer chromatography (TLC) on Merck aluminium silica gel (60 F254) sheets that were visualised under a UV lamp. Evaporation was performed <italic>in vacuo</italic> (rotating evaporator). Sodium sulphate was always used as the drying agent. Commercially available chemicals were purchased from Sigma-Aldrich.</p><sec id="S0002-S2001-S3001" disp-level="3"><label>2.1.1.</label><title>General procedure for the synthesis of amino alcohols 1&#x02013;13</title><p>A solution of the proper oxime (<bold>17</bold>&#x02013;<bold>27</bold>) (10&#x02009;mmol) in anhydrous DMF (10&#x02009;ml) was added portionwise to a solution of MeONa in MeOH (30&#x02009;ml), prepared from anhydrous MeOH (30&#x02009;ml) and Na (11&#x02009;mmol). The reaction mixture was stirred at 60&#x02009;&#x000b0;C for 1&#x02009;h and then cooled at rt. Epichlorohydrin (0.86&#x02009;ml, 11&#x02009;mmol) dissolved in anhydrous DMF (10&#x02009;ml) was added dropwise, and the resulting mixture was stirred for 1&#x02009;h at rt, poured into water (100&#x02009;ml) and extracted with CHCl<sub>3</sub> (2&#x02009;&#x000d7;&#x02009;100mL). The organic phases were combined, washed with water (2&#x02009;&#x000d7;&#x02009;200&#x02009;ml), dried (Na<sub>2</sub>SO<sub>4</sub>) filtered and evaporated under reduced pressure. The crude was distilled <italic>in vacuo</italic> affording an oil corresponding to the proper epoxide (<bold>28</bold>&#x02013;<bold>38</bold>, yield 75&#x02013;85%). NMR data of <bold>28</bold>&#x02013;<bold>35</bold> were in accordance with those reported in literature<xref rid="CIT0025" ref-type="bibr"><sup>25&#x02013;33</sup></xref>.</p><p><italic>(E)-4-Chlorobenzaldehyde O-oxiran-2-ylmethyl oxime (</italic><bold><italic>36</italic></bold><italic>)</italic>: yield 76%; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>): &#x003b4; 8.40 (s, 1H), 7.35 (m, 2H), 7.30 (m, 2H), 4.38 (dd, <italic>J</italic>&#x02009;=&#x02009;12.3&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;3.5&#x02009;Hz, 1H), 4.13 (dd, <italic>J</italic>&#x02009;=&#x02009;12.3&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;3.5&#x02009;Hz, 1H), 3.28&#x02013;3.32 (m, 1H), 2.88 (dd, <italic>J</italic>&#x02009;=&#x02009;5.2&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;4.2&#x02009;Hz, 1H), 2.70 (dd, <italic>J</italic>&#x02009;=&#x02009;5.2&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;4.2&#x02009;Hz, 1H).</p><p><italic>(E)-2-Chlorobenzaldehyde O-oxiran-2-ylmethyl oxime (</italic><bold><italic>37</italic></bold><italic>)</italic>: yield 82%; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>): &#x003b4; 8.34 (s, 1H), 7.37 (m, 2H), 7.28&#x02013;7.24 (m, 2H), 4.35 (dd, <italic>J</italic>&#x02009;=&#x02009;12.3&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;3.5&#x02009;Hz, 1H), 4.06 (dd, <italic>J</italic>&#x02009;=&#x02009;12.3&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;3.5&#x02009;Hz, 1H), 3.30&#x02013;3.34 (m, 1H), 2.90 (dd, <italic>J</italic>&#x02009;=&#x02009;5.2&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;4.2&#x02009;Hz, 1H), 2.76 (dd, <italic>J</italic>&#x02009;=&#x02009;5.0&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;4.2&#x02009;Hz, 1H).</p><p><italic>(E)-3-Chlorobenzaldehyde O-oxiran-2-ylmethyl oxime (</italic><bold><italic>38</italic></bold><italic>)</italic>: yield 79%; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>): &#x003b4; 8.51 (s, 1H), 7.34&#x02013;7.28 (m, 1H), 7.26&#x02013;7.23 (m, 3H), 4.32 (dd, <italic>J</italic>&#x02009;=&#x02009;12.1&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;3.7&#x02009;Hz, 1H), 4.18 (dd, <italic>J</italic>&#x02009;=&#x02009;12.1&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;3.7&#x02009;Hz, 1H), 3.31&#x02013;3.35 (m, 1H), 2.88 (dd, <italic>J</italic>&#x02009;=&#x02009;5.0&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;4.1&#x02009;Hz, 1H), 2.67 (dd, <italic>J</italic>&#x02009;=&#x02009;5.0&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;4.1&#x02009;Hz, 1H).</p><p>A stirred solution of epoxide (<bold>28</bold>&#x02013;<bold>38</bold>, 10&#x02009;mmol) in dry benzene (6&#x02009;ml) was treated with an excess of isopropylamine or <italic>tert</italic>-butylamine (50&#x02009;mmol). The reaction mixture was stirred for 12&#x02009;h at 90&#x02009;&#x000b0;C, and then evaporated. The crude was dissolved in a mixture of MeOH/EtOH 3:7 (20&#x02009;ml) and treated with 1.2 equivalent of the proper organic acid (oxalic, malic or fumaric acids) to give the corresponding amino alcohol (<bold>1</bold>&#x02013;<bold>13</bold>) as a white solid salt.</p><p><italic>(E)-2,3-Dihydro-1H-inden-1-one O-(3-(tert-butylamino)-2-hydroxypropyl) oxime maleate</italic>
<bold>1</bold>: Maleate salt. <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>): &#x003b4; 9.51 (s, 1H), 7.94 (s, 1H), 7.61 (d, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, 1H), 7.34&#x02013;7.31(m, 2H), 7.26&#x02013;7.23 (m, 1H), 6.18 (s, 2H), 4.43&#x02013;4.38 (m, 1H), 4.29 (dd, <italic>J</italic>&#x02009;=&#x02009;4.08&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;12&#x02009;Hz, 1H), 4.19 (dd, <italic>J</italic>&#x02009;=&#x02009;6.0&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;11.6&#x02009;Hz, 1H), 3.21&#x02013;3.28 (m, 1H); 3.05&#x02013;3.02 (m, 3H), 2.90&#x02013;2.87 (m, 2H), 1.43 (s, 9H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 167.7, 163.5, 148.9, 136.6, 135.8, 131.1, 127.5, 126.4, 121.4, 75.7, 66.1, 56.8, 44.4, 28.5, 26.8, 25.45.</p><p><italic>(E)-Benzaldehyde O-(3-(tert-butylamino)-2-hydroxypropyl) oxime maleate</italic>
<bold>2</bold>: Maleate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 8.32 (s, 1H), 7.65&#x02013;7.62 (m, 2H), 7.45&#x02013;7.44 (m, 3H), 6.02 (s, 2H), 4.14&#x02013;4.13 (m, 2H), 3.70&#x02013;3.67 (m, 1H), 3.11&#x02013;3.08 (m, 1H), 2.88&#x02013;2.83 (m, 1H), 1.28 (s, 9H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 167.2, 149.5, 136.1, 131.7, 130.1, 128.8, 126.9, 75.4, 65.5, 56.4, 43.9, 25.0.</p><p><italic>Propan-2-one O-(3-(tert-butylamino)-2-hydroxypropyl) oxime oxalate</italic>
<bold><italic>3</italic></bold>: oxalate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 4.00&#x02013;3.87 (m, 3H), 2.99 (dd, <italic>J</italic>&#x02009;=&#x02009;2.4&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;12.4&#x02009;Hz, 1H), 2.76 (dd, <italic>J</italic>&#x02009;=&#x02009;9.1&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;12.4&#x02009;Hz, 1H), 1.81 (s, 3H), 1.26 (s, 9H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 164.7, 155.0, 74.4, 65.5, 56.0, 44.1, 25.0, 21.2.</p><p><italic>(E)-4-Methoxybenzaldehyde O-(3-(tert-butylamino)-2-hydroxypropyl) oxime maleate</italic>
<bold>4</bold>: Maleate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 8.24 (s, 1H), 7.58 (m, 2H), 7.02 (m, 2H), 6.01 (s, 2H), 4.27&#x02013;4.07 (m, 6H), 3.33 (s, 3H), 3.15&#x02013;3.05 (m, 1H), 2.94&#x02013;2.89 (m, 1H), 1.27 (s, 9H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 165.4, 161.2, 149.4, 128.9, 124.7, 114.8, 75.8, 65.9, 56.5, 55.7, 44.6, 25.4.</p><p><italic>(E)-3-Methoxybenzaldehyde O-(3-(tert-butylamino)-2-hydroxypropyl) oxime oxalate</italic>
<bold>5</bold>: Oxalate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 8.27 (s, 1H), 7.35 (t, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, 2H), 7.21&#x02013;7.17 (m, 2H), 7.01 (dd, <italic>J</italic>&#x02009;=&#x02009;1.6&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;8&#x02009;Hz, 1H), 4.12&#x02013;4.05 (m, 3H), 3.77 (s, 3H), 3.09&#x02013;3.06 (m, 1H), 2.86&#x02013;2.81 (m, 1H), 1.28 (s, 9H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 165.4, 159.9, 149.8, 133.6, 130.4, 119.9, 116.5, 112.1, 76.1, 65.9, 56.5, 55.6, 44.6, 25.4.</p><p><italic>(E)-2-Methoxybenzaldehyde O-(3-(tert-butylamino)-2-hydroxypropyl) oxime oxalate</italic>
<bold><italic>6</italic></bold>: Oxalate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 8.42 (s, 1H), 7.65 (dd, <italic>J</italic>&#x02009;=&#x02009;1.6&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;8&#x02009;Hz, 2H), 7.43 (m, 1H), 7.10 (d, <italic>J</italic>&#x02009;=&#x02009;8&#x02009;Hz, 1H), 6.99 (t, <italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;Hz, 1H), 4.11&#x02013;4.05 (m, 3H), 3.83 (s, 3H), 3.07 (bd, <italic>J</italic>&#x02009;=&#x02009;12&#x02009;Hz, 1H), 2.86&#x02013;2.83 (m, 1H), 1.28 (s, 9H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 165.2, 157.7, 145.2, 132.2, 126.3, 121.1, 120.0, 112.4, 76.0, 65.6, 56.2, 50.2, 47.3, 19.2.</p><p><italic>(E)-3-Chlorobenzaldehyde O-(3-(tert-butylamino)-2-hydroxypropyl) oxime oxalate</italic>
<bold>7</bold>: Oxalate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 8.32 (s, 1H), 7.68 (m, 1H), 7.60&#x02013;7.59 (m, 1H), 7.50&#x02013;7.47 (m, 2H), 4.15&#x02013;4.05 (m, 3H), 3.08&#x02013;3.05 (bd, <italic>J</italic>&#x02009;=&#x02009;12&#x02009;Hz, 1H), 2.83 (dd, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;12.4, 1H), 1.27 (s, 9H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 165.4, 148.6, 134.4, 131.3, 130.3, 126.9, 125.9, 76.3, 65.9, 56.5, 44.6, 25.5.</p><p><italic>(E)-4-Chlorobenzaldehyde O-(3-(tert-butylamino)-2-hydroxypropyl) oxime</italic> oxalate <bold>8</bold>: Oxalate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 8.32 (s, 1H), 7.68 (m, 1H), 7.65 (m, 2H), 7.51 (m, 2H), 4.14&#x02013;4.09 (m, 3H), 3.09&#x02013;3.05 (bd, <italic>J</italic>&#x02009;=&#x02009;12.4&#x02009;Hz, 1H), 2.83 (m, 1H), 1.27 (s, 9H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 165.4, 148.6, 134.4, 131.2, 130.2, 126.9, 125.9, 76.3, 65.9, 56.5, 44.6, 25.4.</p><p><italic>Cyclohexanone O-(2-hydroxy-3-(isopropylamino)propyl) oxime</italic> oxalate <bold>9</bold>: Oxalate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 3.90&#x02013;3.83 (m, 3H), 3.01&#x02013;2.98 (m, 1H), 2.80&#x02013;2.77 (m, 1H), 2.67&#x02013;2.63 (m, 1H), 2.40&#x02013;2.38 (m, 2H), 2.12 (t, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, 2H), 1.61&#x02013;1.48 (m, 6H), 1.08 (d, <italic>J</italic>&#x02009;=&#x02009;6.4&#x02009;Hz, 6H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 165.35, 160.0, 75.5, 67.0, 49.4, 31.8, 27.0, 25.7, 25.2.</p><p><italic>(E)-1,7,7-Trimethylbicyclo[2.2.1]heptan-2-one O-(2-hydroxy-3-(isopropylamino)propyl) oxime fumarate</italic>
<bold>10</bold>: Fumarate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 6.47 (s, 1H), 4.00&#x02013;3.91 (m, 2H), 3.87&#x02013;3.82 (m, 1H), 3.24&#x02013;3.21 (m, 1H), 2.96&#x02013;2.93 (m, 1H), 2.78&#x02013;2.76 (m, 1H), 2.50&#x02013;2.40 (m, 2H), 1.93 (dd, <italic>J</italic>&#x02009;=&#x02009;2.4&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;17.6&#x02009;Hz, 1H), 1.86 (t, <italic>J</italic>&#x02009;=&#x02009;3.2&#x02009;Hz, 1H), 1.78&#x02013;1.74 (m, 1H), 1.71&#x02013;1.64 (m, 1H), 1.32&#x02013;1.28 (m, 1H), 1.18 (t, <italic>J</italic>&#x02009;=&#x02009;6.0&#x02009;Hz, 6H), 0.91 (s, 3H), 0.87 (s, 3H), 0.71 (s, 3H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 169.2, 168.3, 135.5, 75.3, 65.9, 51.8, 49.7, 48.2, 43.5, 33.9, 27.2, 19.6, 19.5, 18.9, 18.7, 11.6.</p><p><italic>Propan-2-one O-(2-hydroxy-3-(isopropylamino)propyl) oxime</italic> oxalate <bold>11</bold>: Oxalate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 4.04&#x02013;3.99 (m, 1H), 3.94 (dd, <italic>J</italic>&#x02009;=&#x02009;5.36&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;11.2&#x02009;Hz, 1H), 3.86 (dd, <italic>J</italic>&#x02009;=&#x02009;5.32&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;11.2&#x02009;Hz, 1H), 3.34&#x02013;3.29 (m, 2H), 3.00 (dd, <italic>J</italic>&#x02009;=&#x02009;2.64&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;12.56&#x02009;Hz, 1H), 2.85&#x02013;2.80 (m, 1H), 1.80 (s, 6H), 1.21 (t, <italic>J</italic>&#x02009;=&#x02009;6.04&#x02009;Hz, 6H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 165.4, 155.4, 75.0, 66.0, 50.1, 47.5, 21.7, 19.2, 18.5.</p><p><italic>(E)-4-Chlorobenzaldehyde O-(2-hydroxy-3-(isopropylamino)propyl) oxime oxalate</italic>
<bold>12</bold>: Oxalate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 8.31 (s, 1H), 7.65 (m, 2H), 7.51 (m, 2H), 4.13&#x02013;4.10 (m, 3H), 3.33&#x02013;3.28 (m, 1H), 3.08&#x02013;3.04 (m, 1H), 2.91&#x02013;2.86 (m, 1H), 1.21 (t, <italic>J</italic>&#x02009;=&#x02009;6.4&#x02009;Hz, 6H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 165.5, 148.6, 134.4, 134.0, 131.2, 130.2, 127.7, 125.9, 76.4, 65.6, 50.1, 47.3, 19.24, 18.7.</p><p><italic>(E)-2-Chlorobenzaldehyde O-(2-hydroxy-3-(isopropylamino)propyl) oxime</italic> oxalate <bold>13</bold>: Oxalate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 8.49 (s, 1H), 7.81 (dd, <italic>J</italic>&#x02009;=&#x02009;1.6&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, 1H), 7.55 (dd, <italic>J</italic>&#x02009;=&#x02009;1.2&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;8&#x02009;Hz, 1H), 7.48 (dt, <italic>J</italic>&#x02009;=&#x02009;1.6&#x02009;Hz, <italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;Hz, 1H), 7.41 (m, 1H), 4.16&#x02013;4.11 (m, 3H), 3.34&#x02013;3.31 (m, 1H), 3.10&#x02013;3.07 (m, 1H), 2.93&#x02013;2.88 (m, 1H), 1.22 (t, <italic>J</italic>&#x02009;=&#x02009;6.4&#x02009;Hz, 6H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 165.25, 146.2, 133.2, 132.2, 130.4, 129.6, 128.1, 127.7, 76.5, 65.6, 50.2, 47.2, 19.2, 18.6.</p></sec><sec id="S0002-S2001-S3002" disp-level="3"><label>2.1.2.</label><title>General procedure for the synthesis of aminoalcohols 14&#x02013;16</title><p>Epichlorohydrin (0.88&#x02009;ml,11.2&#x02009;mmol) was added dropwise to a stirred solution of <italic>N-</italic>hydroxy-5-norbornene-2,3-dicarboximide (2&#x02009;g, 11.2&#x02009;mmol) and Et<sub>3</sub>N (3.12&#x02009;ml, 22.4&#x02009;mmol) in anhydrous DMF (8&#x02009;ml). After stirring for 18&#x02009;h at rt the reaction mixture was poured into water (50&#x02009;ml) and extracted with CHCl<sub>3</sub> (2&#x000d7;50mL). The organic phases were combined, washed with water (2&#x02009;&#x000d7;&#x02009;100&#x02009;ml), dried (Na<sub>2</sub>SO<sub>4</sub>) filtered and evaporated under reduced pressure. The crude epoxide <bold>39</bold> was purified by crystallisation with <italic>n</italic>-hexane. NMR data were in accordance with those reported in literature<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>.</p><p>A stirred solution of epoxide <bold>39</bold> (611&#x02009;mg, 2.6&#x02009;mmol) in dry EtOH (8&#x02009;ml) was treated with an excess of iPrNH<sub>2</sub> (0.43&#x02009;ml, 5&#x02009;mmol) or t-BuNH<sub>2</sub> (0.52&#x02009;ml, 5&#x02009;mmol). The reaction mixture was stirred at 50&#x02009;&#x000b0;C for 4&#x02009;h, and then the solvent was evaporated. The crude was constituted principally by the amino alcohol <bold>40</bold> (iPr) or <bold>41</bold>(tBu) and it was used in the next reaction step without further purification.</p><p>A solution of the proper amino alcohol <bold>40</bold> or <bold>41</bold> (1.56&#x02009;mmol) in 7.8&#x02009;ml of NH<sub>3</sub>-MeOH 7&#x02009;N was stirred rt for 2&#x02009;h. The resulting mixture was filtered and evaporated. The crude was purified by flash chromatography with EtOAc/MeOH/Et<sub>3</sub>N (8: 1.5: 0.5) affording derivative <bold>42</bold> or <bold>43</bold> (60&#x02013;63% yield). NMR data were in accordance with those reported in literature<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>.</p><p>A solution of <italic>p</italic>-, <italic>m</italic>-, or <italic>o</italic>- hydroxybenzaldehyde (6.75&#x02009;mmol) in EtOH (11.4&#x02009;ml) and the proper oxyamine <bold>42</bold> or <bold>43</bold> (6.75&#x02009;mmol) was refluxed for 12&#x02009;h. After cooling, the mixture was evaporated. The crude was dissolved in a mixture of MeOH/EtOH 3:7 (20&#x02009;ml) and treated with 1.2 equivalent of the proper organic acid (oxalic, malic or fumaric acids) affording the amino alcohols (<bold>14</bold>&#x02013;<bold>16</bold>, 70&#x02013;80% yields) as white solids after crystallisation from MeOH/Et<sub>2</sub>O.</p><p><italic>(E)-2-Hydroxybenzaldehyde O-(2-hydroxy-3-(isopropylamino)propyl) oxime maleate</italic>
<bold>14</bold>: Maleate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 9.99(bs, 1H), 8.43 (s, 1H), 8.29 (bs, 1H), 7.54 (d, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, 2H), 7.27 (m, 1H), 6.90 (d, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, 1H), 6.85 (t, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, 1H), 6.01 (s, 2H), 5.76 (m, 1H), 4.12&#x02013;4.07 (m, 3H), 3.33&#x02013;3.30 (m, 1H), 3.09&#x02013;3.07 (m, 1H), 2.90&#x02013;2.89 (m, 1H), 1.22 (m, 6H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 167.6, 156.5, 147.4, 132.0, 127.4, 119.9, 117.8, 116.7, 75.9, 65.7, 50.3, 47.1, 19.3, 18.5.</p><p><italic>(E)-3-Hydroxybenzaldehyde O-(3-(tert-butylamino)-2-hydroxypropyl) oxime fumarate</italic>
<bold>15</bold>: Fumarate salt. <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 8.17 (s, 1H), 7.21 (t, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, 1H), 7.04&#x02013;7.00 (m, 2H), 6.82&#x02013;6.80 (m, 2H), 6.40 (s, 1H), 4.07&#x02013;4.06 (m, 2H), 4.02&#x02013;3.94 (m, 1H), 2.89&#x02013;2.86 (m, 1H), 2.71&#x02013;2.66 (m, 1H), 1.18 (s, 9H). <sup>13&#x02009;</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 169.8, 158.2, 149.7, 133.5, 130.3, 118.6, 117.7, 113.3, 76.4, 66.6, 54.5, 45.0, 26.5.</p><p><italic>(E)-4-Hydroxybenzaldehyde O-(3-(tert-butylamino)-2-hydroxypropyl) oxime fumarate</italic>
<bold>16</bold>: <sup>1</sup>H NMR (400&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 8.12 (s, 1H), 7.42 (m, 2H), 6.80 (m, 2H), 6.40 (s, 1H), 4.02&#x02013;3.97 (m, 3H), 3.04&#x02013;3.00 (m, 1H), 2.87&#x02013;2.83 (m, 1H), 2.70&#x02013;2.65 (m, 1H), 1.10 (d, <italic>J</italic>&#x02009;=&#x02009;6.4&#x02009;Hz, 6H).<sup>13</sup>C NMR (100&#x02009;MHz, DMSO-d<sub>6</sub>): &#x003b4; 169.0, 159.8, 149.3, 129.0, 123.1, 116.1, 76.4, 66.9, 49.4, 48.9, 21.1, 20.7.</p></sec></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Carbonic anhydrase activation</title><p>A stopped-flow method<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref> has been used for assaying the CA catalysed CO<sub>2</sub> hydration activity with Phenol red as indicator, working at the absorbance maximum of 557&#x02009;nm, following the initial rates of the CA-catalysed CO<sub>2</sub> hydration reaction for 10&#x02013;100&#x02009;s. For each activator, at least six traces of the initial 5&#x02013;10% of the reaction have been used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of activator (0.1&#x02009;mM) were prepared in distilled-deionised water and dilutions up to 0.1&#x02009;nM were done thereafter with the assay buffer. The activation constant (K<sub>A</sub>), defined similarly with the inhibition constant (K<sub>I</sub>), was obtained by considering the classical Michaelis&#x02013;Menten equation (<xref ref-type="disp-formula" rid="M0004">Equation 4</xref>), which has been fitted by nonlinear least squares by using PRISM 3:
<disp-formula id="M0004"><label>(4)</label><alternatives><graphic xlink:href="IENZ_A_1838501_M0004.jpg" position="float" orientation="portrait"/><mml:math id="d2e1196"><mml:mrow><mml:mi mathvariant="normal">v</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mi mathvariant="normal">v</mml:mi></mml:mrow><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mrow><mml:mo stretchy="true">{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mi mathvariant="normal">K</mml:mi></mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:msub><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">A</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mi mathvariant="normal">f</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi mathvariant="normal">K</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">}</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula>
where [A]<sub>f</sub> is the free concentration of activator.</p><p>Working at substrate concentrations considerably lower than K<sub>M</sub> ([S]&#x0226a;K<sub>M</sub>), and considering that [A]<sub>f</sub> can be represented in the form of the total concentration of the enzyme ([E]<sub>t</sub>) and activator ([A]<sub>t</sub>), the obtained competitive steady-state equation for determining the activation constant is given by <xref ref-type="disp-formula" rid="M0005">Equation (5)</xref>:
<disp-formula id="M0005"><label>(5)</label><alternatives><graphic xlink:href="IENZ_A_1838501_M0005.jpg" position="float" orientation="portrait"/><mml:math id="d2e1286"><mml:mrow><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">&#x000a0;</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">v</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msub><mml:msub><mml:mi mathvariant="normal">K</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mo>{</mml:mo><mml:msub><mml:mi mathvariant="normal">K</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">A</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:msub><mml:mo>&#x02013;</mml:mo><mml:mn>0.5</mml:mn><mml:mo stretchy="true">{</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">A</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mtext>K</mml:mtext></mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>&#x02013;</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">A</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mtext>K</mml:mtext></mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>&#x02013;</mml:mo><mml:mn>4</mml:mn><mml:msub><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">A</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:msub><mml:msubsup><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mi>t</mml:mi><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:msubsup><mml:mo>}</mml:mo><mml:mo>}</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>
where v<sub>0</sub> represents the initial velocity of the enzyme-catalysed reaction in the absence of an activator<xref rid="CIT0035" ref-type="bibr"><sup>35&#x02013;37</sup></xref>. Enzyme concentrations in the assay system were in the range of 9&#x02013;12&#x02009;nM.</p></sec></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Results and discussion</title><sec id="S0003-S2001" disp-level="2"><label>3.1.</label><title>Chemistry</title><p>As mimic of the main proton shuttling residue (i.e. histidine), histamine (<xref ref-type="fig" rid="F0001">Figure 1</xref>) is the main lead for designing CAAs<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>. The binding mode of histamine with hCA II was elucidated by X-ray crystallography (<xref ref-type="fig" rid="F0002">Figure 2</xref>)<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>. In the CAA/enzyme adduct, a complex network of H-bonds involve the Zn-bound water molecule, His64 and the imidazole ring of the activator, located far away from the metal ion (<xref ref-type="fig" rid="F0002">Figure 2</xref>). Successive X-ray crystallographic studies showed that many other amines and amino acids (<xref ref-type="fig" rid="F0001">Figure 1</xref>) bind in this area and share flexible tails decorated with protonable moieties (<xref ref-type="fig" rid="F0002">Figure 2</xref>)<xref rid="CIT0038" ref-type="bibr"><sup>38&#x02013;40</sup></xref>. No isoform-selective CAAs were detected so far among these amines and amino acid derivatives, except for few exceptions (e.g. histamine shows a 10&#x02009;nM K<sub>A</sub>s against hCAs VA and XIV but is a micromolar activator of the remaining isoforms)<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. The molecule of histamine has been extensively modified (<xref ref-type="fig" rid="F0003">Figure 3</xref>), including substituents on the imidazole C atoms (<bold>A</bold>)<xref rid="CIT0041" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="CIT0042" ref-type="bibr"><sup>42</sup></xref>, replacing the imidazole ring with other heterocycles, such as 2,4,6-trisubstituted pyridinium (<bold>B</bold>), 1,3,4-thiadiazole (<bold>C</bold>) or a combination of these two ring systems (<bold>D</bold>)<xref rid="CIT0043" ref-type="bibr"><sup>43</sup></xref><sup>,</sup><xref rid="CIT0044" ref-type="bibr"><sup>44</sup></xref> and functionalising the NH<sub>2</sub> group, as in carboxamides/ureas/thioureas (<bold>E</bold>)<xref rid="CIT0045" ref-type="bibr"><sup>45</sup></xref>, sulphonamides (<bold>F</bold>)<xref rid="CIT0046" ref-type="bibr"><sup>46</sup></xref>, arylsulfonylureas (<bold>G</bold>)<xref rid="CIT0047" ref-type="bibr"><sup>47</sup></xref>, bis-histamine (<bold>H</bold>)<xref rid="CIT0048" ref-type="bibr"><sup>48</sup></xref><sup>,</sup><xref rid="CIT0049" ref-type="bibr"><sup>49</sup></xref>, oligopeptides<xref rid="CIT0049" ref-type="bibr"><sup>49</sup></xref><sup>,</sup><xref rid="CIT0050" ref-type="bibr"><sup>50</sup></xref>, or imidazole/imidazoline derivatives of the alkaloyd spinaceamine<xref rid="CIT0051" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="CIT0052" ref-type="bibr"><sup>52</sup></xref> and drug clonidine<xref rid="CIT0053" ref-type="bibr"><sup>53</sup></xref> (<xref ref-type="fig" rid="F0003">Figure 3</xref>) were reported to possess improved CA activatory profile when potency and isoform selectivity are concerned.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Natural amino acids and amines investigated for the activation of catalytically active hCA isoforms.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1838501_F0001_B"/></fig><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Superimposition of CAA &#x02013; hCA II complexes as determined by X-ray crystallography. (A) Surface view: the hydrophobic half of the active site is coloured red; His<xref rid="CIT0064" ref-type="bibr"><sup>64</sup></xref> is coloured green and the hydrophilic half in blue. (B) Ribbon active site view. The activators are histamine, in green (PDB 1AVN); L-His, in magenta (PDB 2ABE); L-Phe, in gold (PDB 2FMG); adrenaline, in cyan (PDB 2HKK).</p></caption><graphic content-type="color" xlink:href="IENZ_A_1838501_F0002_C"/></fig><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Histamine-based carbonic anhydrase activators.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1838501_F0003_B"/></fig><p>Interestingly, pharmacological agents born for other medical applications (<xref ref-type="fig" rid="F0004">Figure 4</xref>) showed also to possess more or less relevant CA-activating effects, among which psychoactive compounds of the amphetamine and methamphetamine family<xref rid="CIT0054" ref-type="bibr"><sup>54</sup></xref>, the selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram<xref rid="CIT0055" ref-type="bibr"><sup>55</sup></xref>, the phosphodiesterase IV inhibitor sildenafil<xref rid="CIT0056" ref-type="bibr"><sup>56</sup></xref>, and the &#x003b2;-blocker amino alcohol derivative timolol<xref rid="CIT0057" ref-type="bibr"><sup>57</sup></xref>. Timolol was taken as lead compound in the present study to design a new series of uncommon CAAs, which do not bear imidazole like scaffolds, intesively explored in the field. The enzyme kinetic method showed that timolol noncompetitively activates hCA I and II by forming of a ternary complex consisting of the enzyme, the substrate, and timolol. Docking studies were used to point out that timolol also binds at the entrance of the active site cavity nearby the proton shuttle residue His64<xref rid="CIT0057" ref-type="bibr"><sup>57</sup></xref>. Thus, a series of aminoalcohol oxime ether derivatives previously shown to possess &#x003b2;-blocking or analgesic/antiarrhythmic activity (compounds <bold>1</bold>&#x02013;<bold>16</bold>)<xref rid="CIT0025" ref-type="bibr"><sup>25&#x02013;32</sup></xref>, was investigated for the activation of a panel of brain hCAs.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Other pharmacological agents showing hCAs activating properties.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1838501_F0004_B"/></fig><p>Compounds <bold>1</bold>&#x02013;<bold>6</bold> and <bold>9</bold>&#x02013;<bold>16</bold> were prepared as previously described (<xref ref-type="scheme" rid="SCH0001 SCH0002">Schemes 1 and 2</xref>)<xref rid="CIT0025" ref-type="bibr"><sup>25&#x02013;32</sup></xref>. Here, an updated synthetic procedure is reported. Moreover, new <sup>1</sup>H NMR and <sup>13&#x02009;</sup>C NMR spectra of final compounds are provided in the experimental section. A fully detailed description is provided for the synthesis of new compounds <bold>7</bold> and <bold>8</bold>, following the same synthetic procedure.</p><fig id="SCH0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Preparation of Amino alcohols <bold>1&#x02013;13</bold>. Reagents and conditions: (i) epichlorohydrin, MeONa/MeOH, dry DMF, 60&#x02009;&#x000b0;C, 1&#x02009;h; (ii) <italic>i</italic>PrNH<sub>2</sub> or <italic>t</italic>BuNH<sub>2</sub>, Benzene, 90&#x02009;&#x000b0;C, 12&#x02009;h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1838501_SCH0001_B"/></fig><p>Amino alcohols <bold>1&#x02013;13</bold> were synthesised as reported in <xref ref-type="scheme" rid="SCH0001">Scheme 1</xref><xref rid="CIT0026" ref-type="bibr"><sup>26&#x02013;32</sup></xref>. Oximes <bold>17&#x02013;27</bold> were treated with epichlorohydrin in strong basic conditions affording epoxides <bold>28&#x02013;38</bold>. The amino alcohols <bold>1&#x02013;13</bold> were obtained by reaction of oxime ethers <bold>28&#x02013;38</bold> with an excess of the proper amine, <italic>i</italic>PrNH<sub>2</sub> or <italic>t</italic>BuNH<sub>2</sub>. The final compounds were purified by crystallisation as organic salts.</p><p>The phenolic derivatives <bold>14</bold>&#x02013;<bold>16</bold> were prepared as described in <xref ref-type="scheme" rid="SCH0002">Scheme 2</xref>. <italic>N-</italic>hydroxy-5-norbornene-2,3-dicarboximide was reacted with epichlorohydrin to give the epoxide <bold>39</bold>. The treatment of <bold>39</bold> with an excess of <italic>i</italic>PrNH<sub>2</sub> or <italic>t</italic>BuNH<sub>2</sub> afforded amino alcohol <bold>40</bold> or <bold>41</bold>. Oxyamines <bold>42</bold> and <bold>43</bold> were obtained by aminolysis with NH<sub>3</sub>-MeOH 7&#x02009;N of <bold>40</bold> or <bold>41</bold>.</p><fig id="SCH0002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>Preparation of Amino alcohols <bold>14&#x02013;16</bold>. Reagents and conditions: (i) epichlorohydrin, Et<sub>3</sub>N, dry DMF, rt, 18&#x02009;h; (ii) <italic>i</italic>PrNH<sub>2</sub> or <italic>t</italic>BuNH<sub>2</sub>, Benzene, 50&#x02009;&#x000b0;C, 4&#x02009;h; (iii) NH<sub>3</sub> MeOH 7&#x02009;N, rt, 2&#x02009;h; (iv) <italic>o</italic>-, <italic>m</italic>-, <italic>p</italic>-hydroxybenzaldehyde, EtOH, 90&#x02009;&#x000b0;C, 12&#x02009;h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1838501_SCH0002_B"/></fig><p>The condensation between derivative <bold>42</bold> or <bold>43</bold> and <italic>o</italic>-, <italic>m</italic>- or <italic>p</italic>-hydroxybenzaldehyde afforded the desired amino alcohols <bold>14</bold>&#x02013;<bold>16</bold>, purified by crystallisation as organic salts.</p><p>All the final compounds have been achieved as organic salt oximes presenting <italic>E</italic> configuration. The configuration of the C=N bound for compounds <bold>1</bold>, <bold>2</bold>, <bold>4</bold>&#x02013;<bold>8</bold>, <bold>12</bold> and <bold>13</bold> was assigned by analogy considering the <italic>E</italic> configuration of starting oximes <bold>17</bold>, <bold>18</bold>, <bold>20&#x02013;22</bold>, <bold>25</bold>&#x02013;<bold>27</bold>. As previously reported, the configuration of <italic>E</italic>-oximes <bold>17, 18, 20</bold>&#x02013;<bold>22, 25</bold>&#x02013;<bold>27</bold> was stable under the following reaction conditions.</p><p>The <italic>E</italic> configuration of amino alcohols <bold>14</bold>&#x02013;<bold>16</bold> was conferred by comparison between the <sup>1</sup>H signals of the iminic protons of compounds <bold>14</bold>&#x02013;<bold>16</bold> with the same signals of final compounds <bold>1</bold>, <bold>2</bold>, <bold>4</bold>&#x02013;<bold>8</bold>, <bold>12</bold> and <bold>13</bold>. The chemical shift of iminic proton signal resulted around &#x003b4; 8.05&#x02013;8.50&#x02009;ppm for all derivatives as usually reported for oximes with <italic>E</italic> configuration.</p></sec><sec id="S0003-S2002" disp-level="2"><label>3.2.</label><title>Carbonic anhydrase activation</title><p>Amino alcohols <bold>1&#x02013;16</bold> were here assayed for their activating properties of 4 catalytically active and physiologically relevant hCA isoforms expressed in human brain, that are: the cytosolic hCA I, II, and VII, and the membrane associated hCA IV<xref rid="CIT0058" ref-type="bibr"><sup>58</sup></xref>. In the CNS context, hCA I is expressed in the motor neurons in human spinal cord<xref rid="CIT0059" ref-type="bibr"><sup>59</sup></xref>. The physiologically dominant isoform hCA II is located both in the choroid plexus, and in oligodendrocytes, myelinated tracts, astrocytes and myelin sheaths in the vertebrates brain<xref rid="CIT0060" ref-type="bibr"><sup>60</sup></xref>. hCA IV is located on the luminal surface of cerebral capillaries, associated with the blood&#x02013;brain barrier, and expressed in layers III and VI in the cortex, thalamus and hippocampus<xref rid="CIT0060" ref-type="bibr"><sup>60</sup></xref><sup>,</sup><xref rid="CIT0061" ref-type="bibr"><sup>61</sup></xref>. CA VII is expressed in the cortex, hippocampus and thalamus<xref rid="CIT0062" ref-type="bibr"><sup>62</sup></xref><sup>,</sup><xref rid="CIT0063" ref-type="bibr"><sup>63</sup></xref>. CA VII might be considered a brain-associated CA as it is predominantly expressed in the brain, and absent in most other tissues. CA VII is also considered a key molecule in age-dependent neuronal pH regulation.</p><p>The CA activation data of these 4 isoforms with amino alcohols <bold>1&#x02013;16</bold> and histamine as standard CAA are shown in <xref rid="t0001" ref-type="table">Table 1</xref>. The following structure&#x02013;activity relationship (SAR) can be worked out:</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Activation data of human CA isoforms I, II, IV and VII with amino alcohols <bold>1&#x02013;16</bold> and histamine as reference CAA by a stopped flow CO<sub>2</sub> hydrase assay<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>. <inline-graphic xlink:href="IENZ_A_1838501_ILG0001_B.jpg" content-type="black-white"/></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th rowspan="2" align="left">Compound</th><th rowspan="2" align="center">R<sub>1</sub></th><th rowspan="2" align="center">R<sub>2</sub></th><th rowspan="2" align="center">Ref</th><th colspan="4" align="center">K<sub>A</sub> (&#x000b5;M)<sup>a</sup><hr/></th></tr><tr><th align="center">hCA I</th><th align="center">hCA II</th><th align="center">hCA IV</th><th align="center">hCA VII</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>1</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0002_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">t</italic>Bu</td><td align="char" char=".">6</td><td align="char" char=".">0.94</td><td align="char" char=".">0.76</td><td align="char" char=".">1.42</td><td align="char" char=".">0.89</td></tr><tr><td align="left"><bold>2</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0003_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">t</italic>Bu</td><td align="char" char=".">1,6</td><td align="char" char=".">4.25</td><td align="char" char=".">0.98</td><td align="char" char=".">6.13</td><td align="char" char=".">0.95</td></tr><tr><td align="left"><bold>3</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0004_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">t</italic>Bu</td><td align="char" char=".">6,7</td><td align="char" char=".">7.54</td><td align="char" char=".">7.19</td><td align="char" char=".">5.94</td><td align="char" char=".">1.03</td></tr><tr><td align="left"><bold>4</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0005_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">t</italic>Bu</td><td align="char" char=".">1</td><td align="char" char=".">1.37</td><td align="char" char=".">6.35</td><td align="char" char=".">4.20</td><td align="char" char=".">2.40</td></tr><tr><td align="left"><bold>5</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0006_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">t</italic>Bu</td><td align="char" char=".">1</td><td align="char" char=".">7.10</td><td align="char" char=".">0.079</td><td align="char" char=".">6.01</td><td align="char" char=".">0.42</td></tr><tr><td align="left"><bold>6</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0007_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">t</italic>Bu</td><td align="char" char=".">1</td><td align="char" char=".">1.26</td><td align="char" char=".">0.31</td><td align="char" char=".">5.29</td><td align="char" char=".">0.13</td></tr><tr><td align="left"><bold>7</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0008_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">t</italic>Bu</td><td align="left">&#x02015;</td><td align="char" char=".">6.02</td><td align="char" char=".">2.48</td><td align="char" char=".">1.01</td><td align="char" char=".">0.74</td></tr><tr><td align="left"><bold>8</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0009_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">t</italic>Bu</td><td align="left">&#x02015;</td><td align="char" char=".">0.92</td><td align="char" char=".">0.47</td><td align="char" char=".">7.13</td><td align="char" char=".">0.24</td></tr><tr><td align="left"><bold>9</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0010_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">i</italic>Pr</td><td align="char" char=".">2,6</td><td align="char" char=".">12.1</td><td align="char" char=".">2.50</td><td align="char" char=".">7.73</td><td align="char" char=".">0.082</td></tr><tr><td align="left"><bold>10</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0011_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">i</italic>Pr</td><td align="char" char=".">3,6</td><td align="char" char=".">8.15</td><td align="char" char=".">1.94</td><td align="char" char=".">1.08</td><td align="char" char=".">0.091</td></tr><tr><td align="left"><bold>11</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0012_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">i</italic>Pr</td><td align="char" char=".">6,7</td><td align="char" char=".">8.14</td><td align="char" char=".">3.27</td><td align="char" char=".">12.9</td><td align="char" char=".">8.86</td></tr><tr><td align="left"><bold>12</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0013_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">i</italic>Pr</td><td align="char" char=".">4</td><td align="char" char=".">9.20</td><td align="char" char=".">4.02</td><td align="char" char=".">3.24</td><td align="char" char=".">1.02</td></tr><tr><td align="left"><bold>13</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0014_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">i</italic>Pr</td><td align="char" char=".">5</td><td align="char" char=".">4.57</td><td align="char" char=".">5.90</td><td align="char" char=".">3.01</td><td align="char" char=".">0.51</td></tr><tr><td align="left"><bold>14</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0015_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">i</italic>Pr</td><td align="char" char=".">1</td><td align="left">n.d</td><td align="left">n.d</td><td align="left">n.d</td><td align="left">n.d</td></tr><tr><td align="left"><bold>15</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0016_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">t</italic>Bu</td><td align="char" char=".">1</td><td align="left">n.d</td><td align="left">n.d</td><td align="left">n.d</td><td align="left">n.d</td></tr><tr><td align="left"><bold>16</bold></td><td align="left"><inline-graphic xlink:href="IENZ_A_1838501_ILG0017_B.gif" content-type="black-white"/></td><td align="left"><italic toggle="yes">i</italic>Pr</td><td align="char" char=".">1</td><td align="left">n.d</td><td align="left">n.d</td><td align="left">n.d</td><td align="left">n.d</td></tr><tr><td align="left"><bold>Histamine</bold></td><td colspan="3" align="center">&#x02013;</td><td align="char" char=".">2.1</td><td align="char" char=".">125</td><td align="char" char=".">25.3</td><td align="char" char=".">37.5</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p><sup>a</sup>From three different assays (errors within &#x000b1; 10% of the reported values).</p></fn></table-wrap-foot></table-wrap><list list-type="roman-lower"><list-item><p>A special mention should be done for phenol derivatives <bold>14&#x02013;16</bold> which, uniquely among amino alcohols <bold>1&#x02013;16</bold>, did not produce any activation of the tested hCAs. In fact, it is worth stressing that CAI properties, rather than as CAAs, are commonly ascribed to the phenolic chemotype. Phenols have been thoroughly reported to anchor to the zinc-bound nucleophile (water molecule or hydroxide ion), that is, by one of the four CA inhibition mechanisms known to date. Surprisingly, neither a significant inhibition was detected by treating CA I, II, IV and VII with phenols <bold>14</bold>&#x02013;<bold>16</bold>. One could speculate that the CAI efficacy of <bold>14&#x02013;16</bold> is counterpoised by their CAA action, hindering its detection by the Stopped Flow assay.</p></list-item><list-item><p>The cytosolic isoform hCA I was moderately activated by all remaining amino alcohols, that are <bold>1&#x02013;13</bold>, with K<sub>A</sub> values in the range of 0.92&#x02013;12.1&#x02009;&#x000b5;M. The <italic>tert</italic>-butylamino derivatives <bold>1&#x02013;8</bold> induce a slightly greater activation of CA I than isopropylamines <bold>9&#x02013;13</bold>. In the <bold>1&#x02013;8</bold> subset, it can be noted that the <italic>o-</italic> or <italic>p-</italic>substitution of the aromatic ring bearing the oxime ether group lower the K<sub>A</sub> values <bold>4</bold>, <bold>6</bold>, <bold>8</bold> up to fivefold with respect to <bold>2</bold> (K<sub>A</sub>s of 1.37, 1.26 and 0.92 vs 4.25&#x02009;&#x000b5;M). In contrast, <italic>m</italic>-substitutions are deleterious for the binding to the target as in <bold>5</bold> and <bold>7</bold> (K<sub>A</sub>s of 7.10 and 6.02&#x02009;&#x000b5;M). The cyclisation of the oxime ether group to the aromatic ring as in <bold>1</bold> led to the second-best CA I activation after <bold>8</bold> (K<sub>A</sub>s of 0.94 vs 0.92&#x02009;&#x000b5;M).</p></list-item><list-item><p>The physiologically most relevant isoform hCA II was activated by most tested amino alcohols more than hCA I (K<sub>A</sub>s in the range 0.079&#x02013;7.19&#x02009;&#x000b5;M), except for compounds <bold>4</bold> and <bold>13</bold> (K<sub>A</sub>s of 6.35 vs 5.90&#x02009;&#x000b5;M). Surprisingly, the <italic>m-</italic>anisole derivative <bold>5</bold> reported a 100-fold enhancement of activation efficacy of hCA II when compared to hCA I (K<sub>A</sub>s of 0.079 vs 7.10&#x02009;&#x000b5;M). Most remaining <italic>tert</italic>-butylamino derivatives showed submicromolar K<sub>A</sub> values, whereas all compounds of the subset <bold>9&#x02013;13</bold> activate hCA II in a low micromolar range (K<sub>A</sub>s in the range 1.94&#x02013;5.90&#x02009;&#x000b5;M). All CAAs reported here were more active towards hCA II than histamine, which is a quite weak activator of this isoform with a K<sub>A</sub> of 125&#x02009;&#x000b5;M.</p></list-item><list-item><p>No submicromolar K<sub>A</sub> values were measured for amino alcohols <bold>1&#x02013;13</bold> as hCA IV activators. Indeed, all K<sub>A</sub>s are in a rather flat low micromolar range (K<sub>A</sub>s in the range 1.01&#x02013;12.9&#x02009;&#x000b5;M), making such a membrane associated isozyme the less activated by the assayed derivatives. Notably, the reference CAA histamine even less activates hCA IV with a K<sub>A</sub> of 25.3&#x02009;&#x000b5;M. No significant differences exist between <italic>tert</italic>-butyl and isopropyl derivatives as for the activation of hCA IV.</p></list-item><list-item><p>The other cytosolic isoform investigated here, hCA VII, was rather potently activated, that is chiefly in a submicromolar range, by most of the compounds reported in this work (K<sub>A</sub>s in the range 0.082&#x02013;8.86&#x02009;&#x000b5;M). All derivatives showed much better activation profile than the reference histamine (K<sub>A</sub> of 37.6&#x02009;&#x000b5;M) towards hCA VII. Contrariwise to the other hCAs tested, the most efficient CAAs are the isopropylamino derivatives <bold>9</bold> and <bold>10</bold>, ethers of secondary oxime with an aliphatic pendant showing medium nanomolar K<sub>A</sub>s values of 82 and 91&#x02009;nM, respectively. Only the oxime ethers of <italic>p-</italic>anisaldehyde and acetone in the isopropylamino and <italic>tert</italic>-butylamino series, respectively, that are compounds <bold>4</bold> and <bold>11</bold>, show K<sub>A</sub>s steadily in a low micromolar range. As this isoform is one of the most widely spread in the brain, and probably involved in crucial metabolic/pH regulation processes, these results are of interest in the search of more effective CA VII activators than the currently available such derivatives.</p></list-item></list></sec></sec><sec id="S0004" disp-level="1"><label>4.</label><title>Conclusions</title><p>In the present study, we described the synthesis and CA activating effects of a series of oxime ether-based amino alcohols towards four hCA isoforms expressed in human brain, that are CA I, II, IV and VII. Except for the phenolic compounds <bold>14&#x02013;16</bold>, all amino alcohol derivatives from this study induce a consistent activation of the tested CAs, with K<sub>A</sub>s spanning from a low micromolar to a medium nanomolar range. Specifically, hCA II and VII, probable main CA targets when CNS diseases are concerned,<xref rid="CIT0058" ref-type="bibr"><sup>58</sup></xref> are most potently activated by these oxime ether derivatives. With K<sub>A</sub>s of 79 and 420&#x02009;nM towards hCA II and VII, respectively and K<sub>A</sub>s for CA I and IV settling in a range 10- to 100-fold higher, derivative <bold>5</bold> from the <italic>tert</italic>-butylamines series turned out as the most potent and selective hCA II activator of the study. On the other hand, a multitude of selective hCA VII activators were identified. Specifically, a mention should be done for derivatives <bold>9</bold> and <bold>10</bold>, from the isopropylamines series, showing a 10- to 100-fold selective hCA VII activation profiles with respect to all other assayed CAs. In this second youth period for CAAs, innovative pharmacological studies made these lately neglected agents to draw attention in the memory therapy and cognitive neurodegenerative disorders, as well as in therapeutic areas, such as phobias, obsessive-compulsive disorder, generalised anxiety, and post-traumatic stress disorders<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>. As hCA VII is a key isoform involved in brain metabolism, the here identified potent and selective hCA VII activators may be considered of interest for investigations of possible therapeutic applications or as lead compounds in search of more potent and selective CAAs. This work might bring new lights on the intricate relationship between CA activation and brain physiology.</p></sec></body><back><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrase activators</article-title>. <source>Future Med Chem</source>
<year>2018</year>;<volume>10</volume>:<fpage>561</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">29478330</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Main</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Locke</surname><given-names>A.</given-names></name></person-group>
<article-title>Activation of carbonic anhydrase by histamine</article-title>. <source>J Biol Chem</source>
<year>1941</year>;<volume>140</volume>:<fpage>LXXXI</fpage>.</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Perrin</surname><given-names>DD.</given-names></name></person-group>
<article-title>A re-investigation of the question of activators of carbonic anhydrase</article-title>. <source>Biochem J</source>
<year>1951</year>;<volume>48</volume>:<fpage>495</fpage>&#x02013;<lpage>503</lpage>.<pub-id pub-id-type="pmid">14838873</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tu</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Silverman</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Forsman</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Role of histidine 64 in the catalytic mechanism of human carbonic anhydrase II studied with a site-specific mutant</article-title>. <source>Biochemistry</source>
<year>1989</year>;<volume>28</volume>:<fpage>7913</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">2514797</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrase activators. Part 4. A general mechanism of action for activators of isozymes I, II and III</article-title>. <source>Rev Roum Chim</source>
<year>1992</year>;<volume>37</volume>:<fpage>411</fpage>&#x02013;<lpage>21</lpage>.</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Briganti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Mangani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Orioli</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators: x-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine</article-title>. <source>Biochemistry</source>
<year>1997</year>;<volume>36</volume>:<fpage>10384</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">9265618</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Balaban</surname><given-names>AT.</given-names></name></person-group>
<article-title>Carbonic anhydrase activators. Part 8. pKa&#x02013;activation relationship in a series of amino acid derivatives activators of isozyme II</article-title>. <source>Rev Roum Chim</source>
<year>1994</year>;<volume>39</volume>:<fpage>107</fpage>&#x02013;<lpage>13</lpage>.</mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal" id="CIT0008-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrases: novel therapeutic applications for inhibitors and activators</article-title>. <source>Nat Rev Drug Discov</source>
<year>2008</year>;<volume>7</volume>:<fpage>168</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">18167490</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0008-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Structure and function of carbonic anhydrases</article-title>. <source>Biochem J</source>
<year>2016</year>;<volume>473</volume>:<fpage>2023</fpage>&#x02013;<lpage>32</lpage>.&#x000a0;<pub-id pub-id-type="pmid">27407171</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0008-gen-4">(c) <person-group person-group-type="author"><name name-style="western"><surname>Neri</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Interfering with pH regulation in tumours as a therapeutic strategy</article-title>. <source>Nat Rev Drug Discov</source>
<year>2011</year>;<volume>10</volume>:<fpage>767</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">21921921</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duda</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural and kinetic analysis of the chemical rescue of the proton transfer function of carbonic anhydrase II</article-title>. <source>Biochemistry</source>
<year>2001</year>;<volume>40</volume>:<fpage>1741</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">11327835</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duda</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Govindasamy</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Agbandje-McKenna</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The refined atomic structure of carbonic anhydrase II at 1.05 A resolution: implications of chemical rescue of proton transfer</article-title>. <source>Acta Crystallogr D Biol Crystallogr</source>
<year>2003</year>;<volume>59</volume>:<fpage>93</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">12499545</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elder</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Tu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ming</surname><given-names>LJ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Proton transfer from exogenous donors in catalysis by human carbonic anhydrase II</article-title>. <source>Arch Biochem Biophys</source>
<year>2005</year>;<volume>437</volume>:<fpage>106</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">15820222</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>GN</given-names></name>, <name name-style="western"><surname>Bonapace</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>PY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation</article-title>. <source>Hum Mutat</source>
<year>2004</year>;<volume>24</volume>:<fpage>272</fpage>.</mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogilvie</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Ohlemiller</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>GN</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase XIV deficiency produces a functional defect in the retinal light response</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2007</year>;<volume>104</volume>:<fpage>8514</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">17485676</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Datta</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>GN</given-names></name>, <name name-style="western"><surname>Rubbelke</surname><given-names>TS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Progressive renal injury from transgenic expression of human carbonic anhydrase IV folding mutants is enhanced by deficiency of p58IPK</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2010</year>;<volume>107</volume>:<fpage>6448</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">20308551</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Karnebeek</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Sly</surname><given-names>WS</given-names></name>, <name name-style="western"><surname>Ross</surname><given-names>CJ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A alterations presents with hyperammonemia in early childhood</article-title>. <source>Am J Hum Genet</source>
<year>2014</year>;<volume>94</volume>:<fpage>453</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">24530203</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Alkon</surname><given-names>DL.</given-names></name></person-group>
<article-title>Carbonic anhydrase gating of attention: memory therapy and enhancement</article-title>. <source>Trends Pharmacol Sci</source>
<year>2002</year>;<volume>23</volume>:<fpage>83</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">11830265</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Alkon</surname><given-names>DL.</given-names></name></person-group>
<article-title>Pharmacological enhancement of synaptic efficacy, spatial learning, and memory through carbonic anhydrase activation in rats</article-title>. <source>J Pharmacol Exp Ther</source>
<year>2001</year>;<volume>297</volume>:<fpage>961</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">11356917</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canto de Souza</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Provensi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activation enhances object recognition memory in mice through phosphorylation of the extracellular signal-regulated kinase in the cortex and the hippocampus</article-title>. <source>Neuropharmacology</source>
<year>2017</year>;<volume>118</volume>:<fpage>148</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">28286213</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Provensi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Carta</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A new kid on the block? Carbonic anhydrases as possible new targets in Alzheimer&#x02019;s disease</article-title>. <source>Int J Mol Sci</source>
<year>2019</year>;<volume>20</volume>:<fpage>4724</fpage>.</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blandina</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Provensi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Passsani</surname><given-names>MB</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase modulation of emotional memory. Implications for the treatment of cognitive disorders</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>1206</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">32401069</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal" id="CIT0021-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ke</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Effects of acetazolamide on cognitive performance during high-altitude exposure</article-title>. <source>Neurotoxicol Teratol</source>
<year>2013</year>;<volume>35</volume>:<fpage>28</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">23280141</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0021-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors</article-title>. <source>Expert Opin Drug Metab Toxicol</source>
<year>2020</year>;<volume>16</volume>:<fpage>297</fpage>&#x02013;<lpage>307</lpage>.&#x000a0;<pub-id pub-id-type="pmid">32172611</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0021-gen-4">(c) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Nicolae</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Popescu</surname><given-names>A.</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors. Part 35. Synthesis of Schiff bases derived from sulfanilamide and aromatic aldehydes: the first inhibitors with equally high affinity towards cytosolic and membrane-bound isozymes</article-title>. <source>Eur J Med Chem</source>
<year>1996</year>;<volume>31</volume>:<fpage>431</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nestler</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Hyman</surname><given-names>SE.</given-names></name></person-group>
<article-title>Animal models of neuropsychiatric disorders</article-title>. <source>Nat Neurosci</source>
<year>2010</year>;<volume>13</volume>:<fpage>1161</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">20877280</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Costa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rani</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The role of carbonic anhydrases in extinction of contextual fear memory</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2020</year>;<volume>117</volume>:<fpage>16000</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32571910</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal" id="CIT0024-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnological use for CO2 capture</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2013</year>;<volume>28</volume>:<fpage>229</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">23379684</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0024-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>De Simone</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group> (<article-title>In)organic anions as carbonic anhydrase inhibitors</article-title>. <source>J Inorg Biochem</source>
<year>2012</year>;<volume>111</volume>:<fpage>117</fpage>&#x02013;<lpage>29</lpage>.&#x000a0;<pub-id pub-id-type="pmid">22192857</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0024-gen-4">(c) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Advances in structure-based drug discovery of carbonic anhydrase inhibitors</article-title>. <source>Expert Opin Drug Discov</source>
<year>2017</year>;<volume>12</volume>:<fpage>61</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">27783541</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gentili</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lapucci</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Macchia</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and beta-adrenergic activity of a series of 3-(substituted-benzylideneaminoxy)propanolamine derivatives</article-title>. <source>Farmaco</source>
<year>1995</year>;<volume>50</volume>:<fpage>519</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">7669190</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macchia</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Balsamo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lapucci</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives</article-title>. <source>J Med Chem</source>
<year>1985</year>;<volume>28</volume>:<fpage>153</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">2857200</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schenone</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bruno</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Ranise</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>O-[2-hydroxy-3-(dialkylamino)propyl]ethers of (+)-1,7,7-trimethyl bicyclo[2.2.1]heptan-2-one oxime (camphor oxime) with analgesic and antiarrhythmic activities</article-title>. <source>Farmaco</source>
<year>2000</year>;<volume>55</volume>:<fpage>495</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">11204752</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krajewska</surname><given-names>M.</given-names></name></person-group>
<article-title>Amino alkanol derivatives of oximes</article-title>. <source>Acta Polonia Pharmaceutica</source>
<year>1977</year>;<volume>34</volume>:<fpage>383</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martani</surname><given-names>A.</given-names></name></person-group>
<article-title>New aromatic oxime ether derivatives with &#x003b2;-blocking activity</article-title>. <source>Farmaco</source>
<year>1975</year>;<volume>30</volume>:<fpage>370</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leclerc</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mann</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wermuth</surname><given-names>CG</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and beta-adrenergic blocking activity of a novel class of aromatic oxime ethers</article-title>. <source>J Med Chem</source>
<year>1977</year>;<volume>20</volume>:<fpage>1657</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">22751</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leclerc</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bieth</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Schwartz</surname><given-names>J.</given-names></name></person-group>
<article-title>Synthesis and beta-adrenergic blocking activity of new aliphatic oxime ethers</article-title>. <source>J Med Chem</source>
<year>1980</year>;<volume>23</volume>:<fpage>620</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">6104730</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breschi</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Macchia</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Manera</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Conformationally restrained &#x003b2;-blocking oxime ethers. 3. Synthesis and &#x003b2;-adrenergic antagonistic activity of diastereomeric anti and syn 2-(5&#x02032;-(3&#x02032;-methyl)isoxazolidinyl)-N-alkylethanolamines</article-title>. <source>Eur J Med Chem</source>
<year>1996</year>;<volume>31</volume>:<fpage>159</fpage>&#x02013;<lpage>63</lpage>.</mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Experimental and computational studies of the isomerization between Z and E isomers of benzaldoximes</article-title>. <source>Jnl Chinese Chemical Soc</source>
<year>2004</year>;<volume>51</volume>:<fpage>1259</fpage>&#x02013;<lpage>66</lpage>.</mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalifah</surname><given-names>RG.</given-names></name></person-group>
<article-title>The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C</article-title>. <source>J Biol Chem</source>
<year>1971</year>;<volume>246</volume>:<fpage>2561</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">4994926</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Innocenti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nishimori</surname><given-names>I</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2007</year>;<volume>17</volume>:<fpage>4107</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">17540561</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pastorekova</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Nishimori</surname><given-names>I</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators: activation of the human tumor-associated isozymes IX and XII with amino acids and amines</article-title>. <source>Bioorg Med Chem</source>
<year>2008</year>;<volume>16</volume>:<fpage>3530</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">18294854</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Nishimori</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Innocenti</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators: an activation study of the human mitochondrial isoforms VA and VB with amino acids and amines</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2007</year>;<volume>17</volume>:<fpage>1336</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">17174092</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temperini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme</article-title>. <source>Chemistry</source>
<year>2006</year>;<volume>12</volume>:<fpage>7057</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">16807956</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temperini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design</article-title>. <source>J Med Chem</source>
<year>2006</year>;<volume>49</volume>:<fpage>3019</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">16686544</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temperini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Innocenti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators: kinetic and x-ray crystallographic study for the interaction of D- and L-tryptophan with the mammalian isoforms I-XIV</article-title>. <source>Bioorg Med Chem</source>
<year>2008</year>;<volume>16</volume>:<fpage>8373</fpage>&#x02013;<lpage>837</lpage>.<pub-id pub-id-type="pmid">18774300</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saada</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Montero</surname><given-names>JL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase I and II activation with mono- and dihalogenated histamine derivatives</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2011</year>;<volume>21</volume>:<fpage>4884</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">21742491</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saada</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Montero</surname><given-names>JL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators</article-title>. <source>Bioorg Med Chem</source>
<year>2014</year>;<volume>22</volume>:<fpage>4752</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25082511</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal" id="CIT0043-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Dinculescu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Balaban</surname><given-names>AT.</given-names></name></person-group>
<article-title>Carbonic anhydrase activators. Part 5. CA II activation by 2,4,6-trisubstituted pyridinium cations with 1-(&#x003c9;-aminoalkyl) side chains</article-title>. <source>Rev Roum Chim</source>
<year>1993</year>;<volume>38</volume>:<fpage>343</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation><mixed-citation publication-type="journal" id="CIT0043-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Pastorekova</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Casini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2004</year>;<volume>14</volume>:<fpage>869</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">15012984</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Barboiu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Luca</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators. Part 14. Synthesis of mono- and bis- pyridinium salt derivatives of 2-amino-5-(2-aminoethyl)- and 2-amino-5-(3-aminopropyl)-1,3,4-thiadiazole, and their interaction with isozyme II</article-title>. <source>Eur J Med Chem</source>
<year>1996</year>;<volume>31</volume>:<fpage>597</fpage>&#x02013;<lpage>606</lpage>.</mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrase activators &#x02013; part 21. Novel activators of isozymes I, II and IV incorporating carboxamido and ureido histamine moieties</article-title>. <source>Eur J Med Chem</source>
<year>2000</year>;<volume>35</volume>:<fpage>31</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">10733601</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Briganti</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Novel carbonic anhydrase isozymes I, II and IV activators incorporating sulfonyl-histamino moieties</article-title>. <source>Bioorg Med Chem Lett</source>
<year>1999</year>;<volume>9</volume>:<fpage>2043</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">10450978</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrase activators. Part 24. High affinity isozymes I, II and IV activators, derivatives of 4-(4-chlorophenylsulfonylureido-amino acyl)ethyl-1H-imidazole</article-title>. <source>Eur J Pharm Sci</source>
<year>2000</year>;<volume>10</volume>:<fpage>29</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">10699381</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal" id="CIT0048-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Draghici</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Akocak</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ethylene bis-imidazoles are highly potent and selective activators for isozymes VA and VII of carbonic anhydrase, with a potential nootropic effect</article-title>. <source>Chem Commun (Camb)</source>
<year>2014</year>;<volume>50</volume>:<fpage>5980</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">24763985</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0048-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Saada</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Montero</surname><given-names>JL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators</article-title>. <source>Bioorg Med Chem</source>
<year>2014</year>;<volume>22</volume>:<fpage>4752</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25082511</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal" id="CIT0049-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Mollica</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Macedonio</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Stefanucci</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Five- and six-membered nitrogen-containing compounds as selective carbonic anhydrase activators</article-title>. <source>Molecules</source>
<year>2017</year>;<volume>22</volume>:<fpage>2178</fpage>.</mixed-citation><mixed-citation publication-type="journal" id="CIT0049-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Maccallini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Di Matteo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vullo</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Indazole, pyrazole, and oxazole derivatives targeting nitric oxide synthases and carbonic anhydrases</article-title>. <source>ChemMedChem</source>
<year>2016</year>;<volume>11</volume>:<fpage>1695</fpage>&#x02013;<lpage>9</lpage>.&#x000a0;<pub-id pub-id-type="pmid">27377568</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0049-gen-4">(c) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Scozzafava</surname><given-names>A.</given-names></name></person-group>
<article-title>Carbonic anhydrase activators: amino acyl/dipeptidyl histamine derivatives bind with high affinity to isozymes I, II and IV and act as efficient activators</article-title>. <source>Bioorg Med Chem</source>
<year>1999</year>;<volume>7</volume>:<fpage>2915</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">10658596</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vistoli</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Aldini</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Fumagalli</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Activation effects of carnosine- and histidine-containing dipeptides on human carbonic anhydrases: a comprehensive study</article-title>. <source>Int J Mol Sci</source>
<year>2020</year>;<volume>21</volume>:<fpage>1761</fpage>.</mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akocak</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lolak</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bua</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Activation of human &#x003b1;-carbonic anhydrase isoforms I, II, IV and VII with bis-histamine schiff bases and bis-spinaceamine substituted derivatives</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>1193</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">31237157</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akocak</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lolak</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bua</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>&#x003b1;-Carbonic anhydrases are strongly activated by spinaceamine derivatives</article-title>. <source>Bioorg Med Chem</source>
<year>2019</year>;<volume>27</volume>:<fpage>800</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">30683554</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiaramonte</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Maach</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Biliotti</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and carbonic anhydrase activating properties of a series of 2-amino-imidazolines structurally related to clonidine1</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>1003</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">32336172</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angeli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vaiano</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Mari</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Psychoactive substances belonging to the amphetamine class potently activate brain carbonic anhydrase isoforms VA, VB, VII, and XII</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2017</year>;<volume>32</volume>:<fpage>1253</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">28936885</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Caccia</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Scozzafava</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2003</year>;<volume>13</volume>:<fpage>2765</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">12873510</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal" id="CIT0056-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Abd&#x000fc;lkadir Coban</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Beydemir</surname><given-names>&#x0015e;</given-names></name>, <name name-style="western"><surname>G&#x000fc;cin</surname><given-names>&#x00130;</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV</article-title>. <source>Bioorg Med Chem</source>
<year>2009</year>;<volume>17</volume>:<fpage>5791</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">19635671</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0056-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbon-versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors?</article-title>
<source>J Enzyme Inhib Med Chem</source>
<year>2018</year>;<volume>33</volume>:<fpage>485</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">29390912</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugimoto</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ikeda</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tsukamoto</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Timolol activates the enzyme activities of human carbonic anhydrase I and II</article-title>. <source>Biol Pharm Bull</source>
<year>2010</year>;<volume>33</volume>:<fpage>301</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">20118557</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="book" id="CIT0058-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Donald</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>, <chapter-title>Human carbonic anhydrases: tissue distribution, physiologic role, and druggability</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name></person-group>, eds. <source>Carbonic anhydrases</source>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>; <year>2019</year> p. <fpage>149</fpage>&#x02013;<lpage>185</lpage>.</mixed-citation><mixed-citation publication-type="journal" id="CIT0058-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery</article-title>. <source>Expert Opin Drug Discov</source>
<year>2020</year>;<volume>15</volume>:<fpage>671</fpage>&#x02013;<lpage>86</lpage>.&#x000a0;<pub-id pub-id-type="pmid">32208982</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0058-gen-4">(c) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>How many carbonic anhydrase inhibition mechanisms exist?</article-title>
<source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>345</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">26619898</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bowser</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Expression of carbonic anhydrase I in motor neurons and alterations in ALS</article-title>. <source>Int J Mol Sci</source>
<year>2016</year>;<volume>17</volume>:<fpage>1820</fpage>.</mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halmi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Parkkila</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Honkaniemi</surname><given-names>J.</given-names></name></person-group>
<article-title>Expression of carbonic anhydrases II, IV, VII, VIII and XII in rat brain after kainic acid induced status epilepticus</article-title>. <source>Neurochem Int</source>
<year>2006</year>;<volume>48</volume>:<fpage>24</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">16271802</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Svichar</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Chesler</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Waheed</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrases CA4 and CA14 both enhance AE3-mediated Cl-HCO3- exchange in hippocampal neurons</article-title>. <source>J Neurosci</source>
<year>2009</year>;<volume>29</volume>:<fpage>3252</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">19279262</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruusuvuori</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Huebner</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Kirilkin</surname><given-names>I</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Neuronal carbonic anhydrase VII provides GABAergic excitatory drive to exacerbate febrile seizures</article-title>. <source>Embo J</source>
<year>2013</year>;<volume>32</volume>:<fpage>2275</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">23881097</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karjalainen</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Haapasalo</surname><given-names>HK</given-names></name>, <name name-style="western"><surname>Aspatwar</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumors</article-title>. <source>BMC Cancer</source>
<year>2018</year>;<volume>18</volume>:<fpage>584</fpage>.<pub-id pub-id-type="pmid">29792187</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64</label><mixed-citation publication-type="journal" id="CIT0064-gen-2">(a) <person-group person-group-type="author"><name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Alterio</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Bua</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Phenyl(thio)phosphon(amid)ate benzenesulfonamides as potent and selective inhibitors of human carbonic anhydrases II and VII counteract allodynia in a mouse model of oxaliplatin-induced neuropathy</article-title>. <source>J Med Chem</source>
<year>2020</year>;<volume>63</volume>:<fpage>5185</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">32364386</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0064-gen-3">(b) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrases and metabolism</article-title>. <source>Metabolites</source>
<year>2018</year>;<volume>8</volume>:<fpage>25</fpage>.&#x000a0;</mixed-citation><mixed-citation publication-type="journal" id="CIT0064-gen-4">(c) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas</article-title>. <source>Expert Opin Ther Pat</source>
<year>2018</year>;<volume>28</volume>:<fpage>709</fpage>&#x02013;<lpage>12</lpage>.&#x000a0;<pub-id pub-id-type="pmid">30217119</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0064-gen-5">(d) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT.</given-names></name></person-group>
<article-title>Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases</article-title>. <source>Expert Opin Ther Pat</source>
<year>2018</year>;<volume>28</volume>:<fpage>713</fpage>&#x02013;<lpage>21</lpage>.&#x000a0;<pub-id pub-id-type="pmid">30175635</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0064-gen-6">(e) <person-group person-group-type="author"><name name-style="western"><surname>Supuran</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Altamimi</surname><given-names>ASA</given-names></name>, <name name-style="western"><surname>Carta</surname><given-names>F.</given-names></name></person-group>
<article-title>Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013&#x02013;2019</article-title>. <source>Expert Opin Ther Pat</source>
<year>2019</year>;<volume>29</volume>:<fpage>781</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">31596641</pub-id></mixed-citation></ref></ref-list></back></article>